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AbstrAct
Rhizobium radiobacter is an uncommon agent of infection and has been associated 
with indwelling intravascular devices such as catheter in immunocompromised 
patients. Here, we report a case of R. radiobacter recovered from blood cultures 
in stem cell transplantation in a pediatric patient and present an extensive 
characterization of its antimicrobial susceptibility profile. The isolate presented 
low MICs to many antimicrobial agents, but high MICs to ceftazidime, piperacillin-
tazobactam, aztreonam, and fosfomycin.
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Species of Rhizobium (formerly named Agrobacterium, which was 
reclassified based on 16S rDNA analysis) are aerobic, non-spore forming, 
oxidase- and catalase-positive, gram-negative microorganisms, affecting 
a wide variety of plants, making it an important concern for agriculture 
industry. Among the Rhizobium species, R. radiobacter is the most 
common agent of infection in humans1,2. Cases of bacteremia, prosthetic 
valve endocarditis, urinary tract infection, peritonitis, and pneumonia have 
been reported1,2. Immunocompromised hosts, especially patients with 
hematological malignancy, bacteremia, and catheter-related bloodstream 
infection are the most prevalence cases2. Bacteremia due to R. radiobacter 
is frequently associated with the presence of an indwelling device such as 
a central venous catheter, probably due to its ability for slime production 
on the surfaces3,4. The outcome of device-associated infection due to R. 
radiobacter is generally favorable compared with other pathogens, such as 
Staphylococcus aureus and S. epidermidis5. 
Here, we report a case of bacteremia due to R. radiobacter in a stem cell 
transplantation patient and we discuss the identification and antimicrobial 
susceptibility profile of the isolate. 
Case
A 7-year-old male patient, diagnosed with hepatosplenic lymphoma, 
underwent chemotherapy and autologous bone marrow transplantation. 
Accomplished pre-transplant conditioning with carmustine, etoposide, cytarabine, 
and melphalan, he developed severe neutropenia. According to the protocol 
of febrile neutropenia, we introduced cefepime (administrated during a week), 
piperacillin/tazobactam (for 2 days), meropenem, and vancomycin. As an 
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antifungal agent, amphotericin B was subsequently 
replaced by micafungin due to toxicity. The patient 
evolved with improved thermal curve, microbial 
cultures without growth of microorganisms, 
completing 14 days of antimicrobial treatment. 
After 2 days of stopping the treatment, the patient 
had fever again, and therefore the antimicrobial 
treatment was restarted with meropenem and 
vancomycin. From a couple of blood samples (one 
from peripheral blood and another from catheter) 
it was verified the presence of rod-shaped, gram-
negative bacteria, presenting oxidase-positive 
reaction and growth on MacConkey’s and blood agar 
after 24 h of incubation at 35ºC. This microorganism 
was submitted to VITEK 2 (bioMérieux, France) and 
MALDI-TOF (Becton Dickinson, USA) automated 
systems, being identified as Rhizobium radiobacter 
by both methods.
According to the results of antimicrobial 
susceptibility profile performed by Etest 
(bioMérieux, France), this isolate presented 
low minimal inhibitory concentrations (MICs) to 
ampicillin/sulbactam, ciprofloxacin, ceftriaxone, 
and carbapenems (table). It is of note that a possible 
catheter-related infection was evidenced, according 
to the time of positivity between peripheral blood 
and blood collected via catheter. The catheter 
was removed and the treatment was completed in 
14 days with 10 mg\Kg meropenem. The patient 
evolved with improved clinical parameters, such as 
decreased inflammatory markers (procalcitonin and 
C-reactive protein), and immune (normal leukocyte 
blood count) reconstitution. A new couple of blood 
cultures were collected and did not show bacterial 
growth, verifying the clearance of the Rhizobium 
infection.




















Table: MICs for the different antimicrobial agents tested for the R. radiobacter isolate.
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DIscussIon
Rhizobium radiobacter has been implicated in 
infections involving prosthetic valve, central venous 
catheter, and other types of medical devices. On 
the other hand, a few studies have pointed R. 
radiobacter as a “true” agent of infection. In fact, 
this microorganism should be included in the list 
of pathogens that cause infection, mainly cases of 
bacteremia, when immunocompromised patients 
are affected, especially in the presence of an 
intravenous catheter.
Additionally, other two situations should be 
considered in cases involving R. radiobacter: 1) 
given the very small number of clinical isolates of 
R. radiobacter encountered in clinical laboratories, 
there are limited data on which to judge how well 
the manual and automated bacterial identification 
systems identify it; and 2) there is no susceptibility 
breakpoints defined for these organisms so far, and 
there are few studies in which R. radiobacter has a 
full characterization of its antimicrobial susceptibility 
by the determination of the MIC3,5-8. In fact, 
most isolates are susceptible to broad-spectrum 
cephalosporins, carbapenems, tetracyclines, 
and gentamicin but not tobramycin8,9.Testing of 
individual isolates is recommended for clinically 
significant cases once that it is unknown the 
intrinsic mechanisms of resistance for the rhizobia 
species.
Some studies have pointed that R. radiobacter 
presents low MICs (inferior to 1 µg/mL in most of 
cases) to the third generation cephalosporins, 
cephamycins, carbapenems, fluoroquinolones, 
tetracycline, nitrofurantoin, and aminoglycosides, 
but high MIC (superior to 8 µg/mL have been 
reported) to penicillins, penicillin/enzyme inhibitors, 
beta-lactam, aztreonam, and  fosfomycin3,6,7. In 
this report, the isolate showed low MICs for many 
antibiotics and presented a high MICs for others, 
mainly aztreonam and fosfomycin (table). For 
therapeutic approaches, cephalosporins (mainly 
cefepime) and ciprofloxacin have been used 
successfully to treat Rhizobium infections6,7,9. Lai 
et al.2 reported in their study a very lower MICs for 
carbapenem agents in comparison to our isolate, 
mainly for meropenem (2 μg/mL for our isolate 
against a range from 0.03 to 0.06 μg/mL for 18 
isolates tested in Lai’s study). For imipenem, a 
similar MIC value was obtained in comparison with 
the findings of Lai et al.2 It is of note that, based on a 
few reports to date, antimicrobial susceptibilities for 
R. radiobacter is variable. There is no consensus 
for type or length of treatment or optimum therapy, 
owing to the small number of cases described to 
date, and these may logically be dictated by the 
clinical response, degree of underlying illness, 
status of the host immune system, and whether 
microbiologic eradication can be documented. 
Also, it is not uncommon to recover R. radiobacter 
from sites of body without obvious pathologic 
effects and thus it may be present simultaneously 
with other bacterial species in mixed flora. It is 
important to note that R. radiobacter should be 
added to the list of pathogens that induce infections 
conditions in patients with malignancy, but mainly 
in pediatric patients. For an empirical and definitive 
antibiotic therapy, it has been considered the use of 
cefepime 2 g intravenously every 8 hours for a total 
of 8-10 days9. In conclusion, we present an unusual 
case of R. radiobacter bacteremia in a stem cell 
transplant patient. The isolate presented low MICs 
to many antimicrobial agents, but high MICs to 
ceftazidime, piperacillin-tazobactam, aztreonam, 
and fosfomycin. Further studies are required to 
characterize the antimicrobial susceptibility profile 
and the underlying resistance mechanisms of this 
pathogen.
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